Press Releases

Back to previous page

ReGen Biologics Initiates Training Program for U.S. Surgeons

February 18, 2009

Hackensack, NJ – February 18, 2009 – ReGen Biologics (OTC: RGBO) (“ReGen”) reported the first surgeon training course in support of U.S. launch for the Menaflex™ collagen meniscus implant.  The focus of the course was to “train the trainers” who will be instrumental in educating U.S. surgeons interested in the Company’s recently cleared device.

The four U.S. surgeons – Dr. Charles Beck of West Jordan, Utah, Dr. Heinz Hoenecke and Dr. James Tasto of San Diego, and Dr. William Montgomery of San Francisco - traveled to Innsbruck, Austria to meet with European surgeons who have been actively implanting the Menaflex device.  The course format allowed participants to share cases, review clinical data, and discuss specifics related to patient selection, surgical technique, and rehabilitation protocol.  The course was coordinated through The Orthopedic Academy, an international network of sports medicine surgeons.

“This is an important step in establishing our U.S. surgeon training program,” said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO.  “The experience gained by surgeons in Europe has proven to be extremely beneficial to our understanding of how to most efficiently share clinical data and technical methods with new surgeons,” Dr. Bisbee continued.

Following the Innsbruck meeting, the U.S. attendees are preparing to support training meetings to take place across the U.S., after the official product introduction which is scheduled for February’s American Academy of Orthopaedic Surgeons meeting in Las Vegas, Nevada.

About The Orthopedic Academy:
The Orthopedic Academy is an international learning network of sports medicine surgeons dedicated to training each other, learning about new, cutting edge procedures and techniques, and pursuing evidence-based surgery.  The Orthopedic Academy provides opportunities for top tier sports medicine surgeons to participate in collaborative research and review and develop new devices and techniques.  For more information visit  www.orthopedicacademy.org.

About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen’s Menaflex™ collagen meniscus implant employs proprietary biological collagen scaffold technology to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus of the knee. The Menaflex device has been cleared for sale in Europe and other countries, and is marketed through ReGen’s European subsidiary, ReGen Biologics AG. The FDA cleared the Menaflex device to be marketed in the United States in December 2008. Visit  www.regenbio.com and  www.menaflex.com for more information.
 
Contact:

Donna Lucchesi
480.634.6923
donna@LBCsuccess.com

This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of ReGen management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2007 annual report on Form 10-K, its most recently issued quarterly report filed on Form 10-Q and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.